We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Therapix Biosciences announced a collaboration between the company and The University of Calgary to further evaluate the analgesic effect of Therapix's CB2R agonist proprietary drug candidate, THX-160.
Therapix Biosciences has announced the progression of its RESPECTRUM product candidate into clinical stage. The company plans to initiate a randomized ...